H1-receptor stimulation induces hyperalgesia through activation of the phospholipase C-PKC pathway

Abstract

The supraspinal cellular events involved in H 1 -mediated hyperalgesia were investigated in a condition of acute thermal pain by means of the mouse hot-plate test. I.c.v. administration of the phospholipase C (PLC) inhibitors U-73122 and neomycin antagonized the hyperalgesia induced by the selective H 1 agonist FMPH. By contrast, U-73343, an analogue of U-73122 used as negative control, was unable to modify the reduction of the pain threshold induced by FMPH. In mice undergoing treatment with LiCl, which impairs phosphatidylinositol synthesis, or treatment with heparin, an IP 3 -receptor antagonist, the hyperalgesia induced by the H 1 -receptor agonist remained unchanged. Similarly, pretreatment with D-myo inositol did not alter the H 1 -induced hypernociceptive response. Neither i.c.v. pretreatment with TMB-8, a blocker of Ca 2+ release from intracellular stores, nor pretreatment with thapsigargin, a depletor of Ca 2+ intracellular stores, prevented the decrease of pain threshold induced by FMPH. On the other hand, i.c.v. pretreatment with the selective protein kinase C (PKC) inhibitors calphostin C and chelerytrine resulted in a dose-dependent prevention of the H 1 -receptor agonist-induced hyperalgesia. The administration of PKC activators, such as PMA and PDBu, did not produce any effect on FMPH effect. The pharmacological treatments employed did not produce any behavioral impairment of mice as revealed by the rota-rod and hole-board tests. These results indicate a role for the PLC-PKC pathway in central H 1 -induced hyperalgesia in mice. Furthermore, activation of PLC-IP 3 did not appear to play a major role in the modulation of pain perception by H 1 -receptor agonists. #

Signalling bias in new drug discovery: detection, quantification and therapeutic impact

“…At present, biased signalling is proposed to be useful in several diseases, including heart failure (β-adrenergic receptors) [97][98][99] , hyperlipidaemia (nicotinic acid receptors) 100,101 , hypertension (α 2 -adrenergic receptors) 102 , some neuropsychiatric and/or neurodegenerative disorders (histamine H 1 receptors) 103 , hypothyroidism (thyroid-stimulating hormone receptor) 104 , small-cell lung cancer (gastrin-releasing peptide (GRP) and vasopressin receptors) 68 , schizophrenia (dopamine D 2 receptors) [105][106][107] , osteoporosis (PTH receptors) 67,108,109 , Parkinson's disease (dopamine D 1 receptors) 110 , diabetes (GLP1 receptors) 69 , as well as addiction, psychosis and depression (5-hydroxytryptamine (5-HT; serotonin) receptors) [111][112][113] .…”

Update on 3-iodothyronamine and its neurological and metabolic actions

“…Other interactions between T1AM signaling and histamine circuitry have been identified. Histamine has been demonstrated to modulate pain at the cortical and subcortical level, inducing hyperalgesia at low doses through H1 receptors (Malmberg-Aiello et al, 1994 ; Galeotti et al, 2004 ). In line with these observations, i.c.v.…”

The Antinociceptive and Anti-inflammatory Action of the CHCl3-Soluble Phase and Its Main Active Component, Damnacanthal, Isolated from the Root of Morinda citrifolia

“…In the former, histamine H 1 and H 2 receptors are involved in the modulation of pain sensations. [15][16][17] In the peripheral nervous system, it is reported that pyrilamine (histamine H 1 receptor antagonist) and cimetidine (histamine H 2 receptor antagonist) show analgesic effects in the formalin test. 18) In addition, anti-histaminic drugs show antinociceptive effects on formalin-induced stimuli.…”